UBS Group’s Transmedics TMDX Stock Holding History

UBS Group’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$99.4K	Buy	+1,000	New	+$130K	﹤0.01%	7003

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's TMDX Position: Q1 2026 in Review

UBS Group reduced its Transmedics (TMDX) stake by 12% in Q1 2026, selling an estimated $10.2M and leaving 580,793 shares worth $57.7M. The position accounts for 0.01% of the portfolio, ranked #1505.

UBS Group first reported a position in TMDX in Q2 2019 and has held it in 28 quarters since. The position peaked at $96.1M in Q3 2025. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

UBS Group held 580,793 shares of Transmedics worth $57.7M as of Q1 2026.
UBS Group sold 78,503 Transmedics shares in Q1 2026, an estimated $10.2M.
Transmedics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1505 holding.
UBS Group first reported a position in Transmedics in Q2 2019 and has held it in 28 quarters since.
UBS Group's Transmedics position peaked at $96.1M in Q3 2025.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.